Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): A meta-analysis  by Li, Jiang-Hong et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 79 (2016) 281e291
www.jcma-online.comOriginal Article
Efficacy and safety of traditional Chinese medicine for the treatment
of influenza A (H1N1): A meta-analysis
Jiang-Hong Li a,*, Re-Qin Wang a, Wen-Jie Guo b, Juan-Sheng Li c
a Tianshui City Center for Disease Control, Gansu, China
b College of Medicine and Nursing, Chendu University, Chendu, Sichuan, China
c Lanzhou University School of Public Health, Lanzhou, Gansu, China
Received February 10, 2015; accepted October 13, 2015AbstractBackground: In March 2009, the first reported case infected with influenza A (H1N1) virus was identified in Mexico. The World Health Or-
ganization officially declared the outbreak to be a pandemic on June 11, 2009. The objective of this study was to evaluate the efficacy and safety
of traditional Chinese medicine (TCM) in the treatment of influenza A (H1N1) infection.
Methods: We electronically and manually searched electronic databases, reference lists, and conference compilations to identify randomized
clinical trials that compared the treatment of influenza A (H1N1) using TCM with a control group receiving oseltamivir or antivirus therapy. The
Jadad score was used to assess trial quality. Duration of viral shedding, time to defervescence, and effective rate were taken as outcome
measurements; additionally, heterogeneity analysis and meta-analysis were performed.
Results: A total of 30 studies were included in our investigation, and these studies together included 3444 cases. Based on the Jadad score, each
of these studies were divided as follows: high-quality studies (n ¼ 3), medium-quality studies (n ¼ 2), and low quality studies (n ¼ 25). A meta
analysis was performed, which indicated that the time to defervescence between the TCM treatment group and the control group was statistically
significant, the duration of viral [Influenza A (H1N1)] shedding in the integrated Chinese and Western medicine subgroups was statistically
significant, but it was not statistically significant between the two groups, the effective rate between the two groups was not statistically sig-
nificant. A total of 18 studies described adverse drug reactions.
Conclusion: The results of our study indicated that the mean time to defervescence in the TCM treatment group was less than noted in the control
group, and that the duration of viral [Influenza A (H1N1)] shedding in the integrated Chinese and Western medicine subgroups was less than that
noted in the control group. However, the available evidence does not consider the fact that the difference in duration of viral shedding and
effective rate between the two groups was statistically similar. No obvious adverse events were reported in the included studies.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).for its unique ability to cause recurrent epidemics and global
pandemics. The ability of this virus to undergo genetic
reshuffling causes unpredictable changes in its antigens and
the consequent immune response leads to recurrent epidemics
of febrile respiratory disease every 1e3 years. In the 20th
century, three influenza pandemics occurred, which resulted in
the deaths of tens of millions of people. Each of these pan-
demics was caused by the appearance of a new strain of the
influenza virus in humans.1e3 In April 2009, the first reportedsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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Mexico. This was a novel influenza virus strain that spread
rapidly around the world. Influenza A (H1N1) virus infection
is associated with a high risk of severe complications and is
spreading more rapidly throughout the world than other re-
ported seasonal influenza types.2,3 The World Health Organi-
zation officially declared the outbreak to be a pandemic on
June 11, 2009.4 Oseltamivir (Tamiflu) and zanamivir
(Relenza) are approved by the US Food and Drug Adminis-
tration (FDA) for use against Type A and Type B influenza
infections. However, it has been thought that the development
of drug resistance may limit the clinical utility of these drugs
in the future.5 Chinese herbs, which are the most important
component of traditional Chinese medicine (TCM), are widely
used in China. Because of the limitation of health care re-
sources and the high cost of antiviral drugs, Chinese herbs
have been recommended for preventing and treating influenza
in China, especially in the poorer regions. In October 2009,
China's Ministry of Health issued Guidelines for Management
of Pandemic (H1N1) 2009 Influenza, and recommended a se-
ries of Chinese herbs for the treatment of Type A influenza A
(H1N1), including extracts from natural herbs, Chinese patent
medicines (including herbal injection), and principles for
individually prescribed herbal decoction.6 However, there has
been no critically assessed evidence such as systematic re-
views or meta-analyses on the potential benefits and harms of
medicinal herbs for influenza A (H1N1) treatment to justify
their clinical use and recommendation.
2. Methods2.1. Data source and search strategyLiterature searches were conducted in the Cochrane Central
Register of Controlled Trials (CENTRAL) in the Cochrane
Library, MEDLINE, Embase, and the Chinese BioMedical
Literature Databases, Chinese National Knowledge Infra-
structure, Chinese Scientific Journal Database, China's
Important Conference Papers Database, and China's Disserta-
tion Database from their inception to November 30, 2014. We
also searched ongoing registered clinical trials listed in the
Chinese Clinical Trial Registry website (http://www.chictr.org/
), and the International Clinical Trial Registry of the US Na-
tional Institutes of Health (http://clinicaltrials.gov/). The
following search terms were used either individually or in
combination: “influenza,” “Influenza A (H1N1),” “Chinese
traditional,” “Chinese herbal,” “oriental traditional,” “herb,”
“herbal medicine,” “clinical trial,” and “randomized controlled
trial.”
Two authors (J.-H.L. and R.-Q.W.) conducted the literature
search and study selection, and data were extracted indepen-
dently. The extracted data included authors and title of the
study, year of publication, study size, age and sex of the
participants, details of methodological information, name and
component of Chinese herbs, treatment process, details of the
control interventions, outcomes (e.g., total effective rate), andadverse effects reported for each study. Disagreement was
resolved by discussion, and consensus was reached through a
third party.2.2. Inclusion criteriaThe following inclusion criteria were applied: (1) study
cases were confirmed to be infected by H1N1 strain, according
to diagnostic criteria that China's Ministry of Health has
promulgated the “Influenza A (H1N1) Diagnosis and Treat-
ment Program” (third edition, 2009); (2) study included key
interventions for medical treatment, including any type of
medicine, such as TCM; diagnosis and treatment using various
types of Chinese medicine formulations (e.g., Chinese medi-
cine, herbs, herbal extracts, and other active ingredients) or
integrated TCM and Western medicine or these in combination
with other therapies, with the control group receiving Western
medicine or placebo; (3) randomized controlled trials (RCTs)
or controlled clinical trials.2.3. Exclusion criteriaStudies were excluded based on the following criteria: (1) if
the study was a repetition of an existing study already pre-
sented in the published literature; (2) if the control in-
terventions contained medicine; (3) if the study involved
nonclinical trials of key interventions for TCM (such as animal
testing, in vitro experiments); and (4) if the study control was
unreasonable, without comparable clinical trials.2.4. Extraction of dataData were obtained directly from medical reports. When
not explicitly stated, data were derived from graphs, tables, or
charts included in the reports or data supplements. The data
collected included the following: report location (country,
state, and city), report dates, and authors. Extracted data
included the duration of viral shedding, time to defervescence,
and effective rate.2.5. Trial quality assessmentTwo authors (R.-Q.W. and W.-J.G.) evaluated the quality of
the included trials. The quality of included trials was assessed
using the Jadad Score to address the following criteria7: (1)
description of the method for determining the sample size; (2)
randomization; (3) description of generated random sequence;
(4) description of allocation concealment; (5) blinded; (6)
double blind; (7) describing the number of participants lost,
where the lost or quit test proportion was less than 10%. If a
study meets all of the aforementioned seven criteria, we assign
the study a Jadad score of 7 (i.e., 1 point for each criterion
met). The quality of trials was assessed as follows: total score
of 0e2, low quality; total score of 3e4, medium quality. total
score of 5e7, high quality. Two reviewers independently
evaluated the studies. In the event of disagreement, further
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party opinion.2.6. Statistical analysisData were summarized using relative risk (RR) with 95%
confidence intervals (CIs) for binary outcomes, or mean dif-
ference (MD) with 95% CI for continuous outcomes. RevMan
(version 5.0.17) was used for data analyses. However, meta-
analysis was utilized if the trials had a good homogeneity of
study design, participants, interventions, control, and outcome
measures, which were assessed by examining I2 (a quantity
that describes approximately the proportion of variation in
point estimates due to heterogeneity rather than sampling
error). Publication bias were to be explored by funnel plot
analysis if sufficient studies were found. If we had identified a
sufficient number of randomized trials, we had planned to
perform sensitivity analyses to explore the influence of trial
quality on effect estimates. The quality components of meth-
odology included adequacy of generation of allocation
sequence, concealment of allocation, double blinding, etc.
3. Results3.1. Description of studiesWe retrieved a total of 287 citations from the aforemen-
tioned databased. Then, upon reading the titles and abstracts,
duplicates were eliminated and research purposes in the papers
were evaluated. At this point, 153 articles were available. Then
studies, interventions, and outcome variables that did not meet
the necessary requirements were eliminated, which brought
down the available articles to 83. The total number was further
reduced by 21 when studies using random method and un-
reasonable control groups were excluded. The final 30 studies
included two English medical literatures. The remaining were
all Chinese literature (Table 1). Again, we used the Jadad
criteria to evaluate the quality of the evaluation; once the
assessment was completed, three studies were designated as
high-quality literature,8e10 two as medium quality,11,12 and 25
as having low quality.1e7,13e38 None of the included studies
reported sample size estimation, and had a maximum sample
size of 300 cases,32 a minimum of 46 cases,35 and all studies
were grouped using a stochastic approach but with no referral
documents to hide a random allocation scheme. In addition,
three studies described the use of blinding.8,10,28 Although all
of the studies reported use of a random method, only 10
detailed the random method used,8,10e12,14,23,25,27,28,31 and five
studies described participant lost and exit records.8,10,11,21,28,37
There were 18 studies that described the adverse drug reac-
tions,8e12,14,15,19e21,23,26e28,30e32,34 eight studies that
addressed experimental group therapy in Integrated Chinese
and Western medicine studies,11,17,21,25,34,36e38 and 22 that
involved simple TCM treatment studies. In most of the studies,
the control group received phosphate oseltamivir treatment
(28 studies); only two studies used other antiviral drugs.14,25
The basic characteristics of these studies are shown in Table 1.3.2. Time to defervescenceThere were 17 studies that reported time to defervescence,
including three of the high- and medium-quality studies.8,11,12
We first analyzed the high- and medium-quality studies. After
the test for heterogeneity ( p ¼ 0.13, I2 ¼ 50%), a lower
heterogeneity was noted by applying a fixed effect model
(MD ¼ 0.02, p ¼ 0.87), although the difference between the
two groups was not statistically significant. The total sample
size in these 17 studies was 1564 cases, and statistical anal-
ysis was performed by calculating MD. Subgroup 1 included
studies employing pure Chinese medicine treatment (n ¼ 13
studies): in five of these studies, the time to defervescence
was more than the control group, but in the eight remaining
studies, it was lesser than the control group. After the test for
heterogeneity ( p ¼ 0.23, I2 ¼ 21%), Subgroup 1 was found to
have a lower heterogeneity. Application of the fixed effects
model (MD ¼ 0.11, p ¼ 0.009) indicated that the difference
was statistically significant (i.e., the time to defervescence in
the pure Chinese medicine group was less than that of the
control group). Subgroup 2 integrated Chinese and Western
medicine therapy studies (n ¼ 4). In this subgroup, the
average time to defervescence was less than that noted in the
control group. After the test for heterogeneity ( p ¼ 0.82,
I2 ¼ 0%), no heterogeneity was noted in Subgroup 2.
Application of the fixed effects model (MD ¼ 0.25,
p ¼ 0.008) indicated that the difference was statistically
significant using a fixed effects model (i.e., the time to
defervescence in the integrated Chinese and Western medi-
cine treatment group was less than that of the control group).
The data of Subgroups 1 and 2 were combined by hypothesis
testing. An analysis of these data indicated statistical signif-
icance ( p < 0.05). Based on this result, it is clear that average
time to defervescence in the TCM treatment group was less
than that of the control group (Fig. 1).3.3. Duration of viral sheddingThere were 12 studies that reported the duration of viral
shedding, including two of the high- and medium-quality
studies.10,11 We first analyzed the high- and medium-quality
studies. After the test for heterogeneity ( p ¼ 0.47,
I2 ¼ 0%), a lower heterogeneity was noted by applying the
fixed effects model (MD ¼ 0.26, p ¼ 0.06), and the difference
between the two groups was not statistically significant. The
total sample in these 12 studies was 1469 cases, and statistical
analysis in these studies was performed by calculating MD.
Subgroup 1 included nine pure Chinese medicine studies, and
Subgroup 2 included three integrated Chinese and Western
medicine studies. After a test for heterogeneity ( p ¼ 0.02,
I2 ¼ 56%), Subgroup 1 was found to have a lower heteroge-
neity. Application of the fixed effects model (MD ¼ 0.07,
statistic Z ¼ 0.96, p ¼ 0.34) indicated that there was no sta-
tistical difference between the groups. After testing for het-
erogeneity ( p ¼ 0.41, I2 ¼ 0%), Subgroup 2 was found to have
a lower heterogeneity. To estimate the combined effect, sub-
groups within each study were combined to affect sample size,
Table 1
Study basic characteristics.
Study Sample Sex
(male/female)
Age Randomization Random
method
Sample
size
estimate
Lost
and
exit
Blind Int ntions Treatment
time (d)
Outcomes Jadad
scale
Experimental
group (E)
Control
group (C)
E C E C E C E C
Chen et al14 2010 48 47 Unclear Unclear Unclear Unclear Yes Random
number
tables
No No No Fanggan dec on Antiviral
drug
3e5 3e5 A, B 2
Liu et al15 2010 64 60 30/34 35/25 19.8 ± 3.7 19.64 ± 1.4 Yes Unclear No No No Lianhuaqing
capsule
Oseltamivir 5 5 A, C 1
Liu et al22 2012 84 84 Unclear Unclear Unclear Unclear Yes Unclear No No No Modified Yi o
Decoction
Oseltamivir 5 5 A 1
Tang et al20 2013 57 63 44/13 43/20 19.7 ± 0.2 20.6 ± 0.3 Yes Unclear No No No Differential
Treatment
Oseltamivir 5 5 A, B, and C 1
Zhang et al24 2011 30 30 17/13 16/14 22.77 ± 3.86 23.37 ± 3.99 Yes Unclear No No No Prescription
TCM
Oseltamivir 5 5 A, B, and C 1
Zhang25 2011 40 40 26/14 25/15 32.1 31.1 Yes Random-
number
tables
No No No Lianhuaqing
capsule þ a ral
drug
Antiviral
drug
Unclear Unclear A, B 2
Zhang et al27 2012 84 84 43/41 42/42 39.16 ± 12.18 37.25 ± 16.13 Yes SAS
ruanjian
No No No Differential
treatment
Oseltamivir 7 7 A, C 2
Zeng et al11 2011 59 55 31/28 25/30 18.52 ± 7.77 19.62 ± 5.58 Yes Random-
number
tables
No Lost
1 case
No Maxinshigan
soup
Oseltamivir 7 7 A, B, and C 3
Study Sample Sex (male/female) Age Randomization Random
method
Sample
size
estimate
Lost
and
exit
Blind Interventio Treatment time (d) Outcomes Jadad
scale
E C E C E C E E C
Xiao et al16 2014 25 33 Unclear Unclear Unclear Unclear Yes Unclear No No No Tianlong compound
preparation
seltamivir 3 3 A 1
Zhao et al26 2011 31 16 27/4 14/2 18.97 ± 2.88 20.06 ± 2.86 Yes Unclear No No No Differential treatment seltamivir 3 3 A and C 1
Zhao et al17 2011 26 24 22/4 21/3 21.35 21.77 Yes Unclear No No No Tanreqing injection þ
oseltamivir
seltamivir 3e10 3e10 A 1
Zheng et al21 2010 52 51 35/17 33/18 17.17 ± 9.50 15.80 ± 9.04 Yes Unclear No No No JuLa Qingdu decoction
oseltamivir
seltamivir A, B, and C 1
Chen et al12 2011 31 55 18/13 30/25 20.06 ± 8.96 19.62 ± 5.58 Yes Random
number
tables
No Lost
2 case
No Differential treatment seltamivir 5 5 A an d B 3
Chen et al8 2010 31 22 18/13 9/13 19.87 ± 9.20 20.68 ± 6.97 Yes Computer
random
number
generator
No Lost
2 cases
Single
blind
Differential treatment seltamivir 5 5 A an d B 5
Ma et al19 2010 133 147 87/46 84/63 22.8 ± 6.0 23.2 ± 8.3 Yes Unclear No No No Differential Treatment seltamivir 5 5e7 A and C 1
Han18 2011 144 65 80/64 37/28 Unclear Unclear Yes Unclear No No No SangJuYin þ Yanhunin seltamivir Unclear Unclear A 1
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Study Sample Sex (male/female) Age Randomization Random
method
Sample
size
estimate
Lost
and
exit
blind Interventions Treatment
time (d)
Outcomes Jadad Scale
E C E C E C E C E C
Liu et al23 2011 31 21 18/13 13/9 19.87 ± 9.20 20.09 ± 5.64 Yes Random
number
tables
No No No Differential treatment Oseltamivir 5 5 A and B 2
Wang et al28 2011 103 103 65/38 58/45 19.6 ± 7.1 18.7 ± 5.3 Yes Random
number
tables
Yes Yes Double
blind
Maxingshiganeyinqiaosan Oseltamivir 5 5 B 6
OuYang et al9 2010 116 58 59/57 31/27 19.23 ± 10.44 19.69 ± 9.91 Yes Unclear No No No Lianhuaqingwen capsule Oseltamivir 3e5 3e5 A 1
Wei and Luo30 2010 30 16 17/13 10/6 17.76 ± 2.68 16.25 ± 6.003 Yes Unclear No No No Lianhuaqingwen capsule Oseltamivir 5 5 B 1
Dou et al29 2010 63 36 Unclear Unclear Unclear Unclear Yes Unclear No No No Fixed prescription Oseltamivir 3e5 3e5 B and C 1
Zhang et al31 2012 56 56 30/26 31/25 20 ± 10.30 22.30 ± 11.6 Yes Random
number
tables
No No No Lianhuaqingwen capsule Oseltamivir 5 5 B and C 2
Weng et al32 2010 150 150 95/55 90/60 10.5 11.2 Yes Unclear No No No Clear solution dampness
soup
Oseltamivir 5 5 A 1
Geng and Yu33 2011 38 30 22/16 19/11 35.1 34.23 Yes Unclear No No No Lianhuaqingwen capsule þ
antiviral drug
Oseltamivir 5 5 B 1
Tu et al34 2013 128 107 91/37 78/29 23.06 ± 6.22 25.11 ± 5.02 Yes Unclear No No No Banlangen þ oseltamivir Oseltamivir 7 7 A 1
Study Sample Sex (male/female) Age Randomization Random
method
Sample
size
estimate
Lost
and
exit
Blind Interventions Treatment
Time (d)
Outcomes Jadad
Scale
E C E C E C E C E C
Tian et al35 2011 40 20 16/24 12/8 22.9 ± 4.3 22.9 ± 6.4 Yes Unclear No No No QingKaiLing (oral) Oseltamivir 5e7 5e7 A an d B 1
Qian et al38 2011 25 29 11/14 16/13 40.91 ± 19.81 41.22 ± 15.62 Yes Unclear No No No Tanreqing injection þ
oseltamivir
Oseltamivir 5 5 A, B, and C 1
Li36 2010 55 55 28/27 32/23 31.35 30.77 Yes Unclear No No No Tanreqing injection þ
oseltamivir
Oseltamivir 5 5 A 1
Chai et al37 2010 23 23 13/10 14/9 22.20 ± 2.38 21.5 ± 2.43 Yes Unclear No No No Differential treatment þ
oseltamivir
Oseltamivir 7 7 A 1
Duan et al10 2011 122 122 64/58 63/59 21.5 ± 5.9 21.4 ± 3.9 Yes Computer
random
number generator
Yes Lost
12 cases
Double
blind
Lianhuaqingwen capsule Oseltamivir 7 7 B and C 6
A ¼ effective rate; B ¼ time to defervescence; C ¼ duration of viral shedding; TCM ¼ traditional Chinese medicine.
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Fig. 1. Meta-analysis of time to defervescence: TCM versus control group. CI ¼ confidence interval; IV ¼ Inverse Variance methods; SD ¼ standard deviation;
TCM ¼ traditional Chinese medicine.
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MD ¼ 0.52, statistic Z ¼ 2.36, and p ¼ 0.02, the difference
between the two groups was statistically significant, indicating
that the duration of viral shedding was less for the integrated
Chinese and Western medicine subgroups Influenza A (H1N1)
than the control group. The combined subgroups used the
random effects model, with statistics after the merger utilizing
hypothesis testing, and the difference being not statistically
significant ( p ¼ 0.77). The current evidence does not indicate
that the difference in the duration of influenza A (H1N1)
shedding between the two groups was not statistically signif-
icant (Fig. 2).3.4. Effective rate analysisIn our review, 26 studies noted an effective rate, which
included three of the high- and medium-quality studies.8,11,12
We first analyzed the high- and medium-quality studies.
After the test for heterogeneity ( p ¼ 0.48, I2 ¼ 0%), a lower
heterogeneity was noted using a fixed effects model (RR ¼ 1,
p ¼ 0.8), and the difference between the two groups was not
statistically significant. The total sample size in these 26studies was 3148 cases. Statistical analyses on 18 TCM studies
and eight integrated Chinese and Western medicine studies
were performed using RR. After a test for heterogeneity
( p ¼ 0.007, I2 ¼ 35%), a higher heterogeneity was noted in
Subgroup 1 using a random effects model analysis [RR ¼ 1.01
(95% CI: 0.99e1.03), statistic Z ¼ 1.32, p ¼ 0.19), and there
was no statistical difference between the groups. After a test
for heterogeneity ( p ¼ 0.1, I2 ¼ 42%), random effects model
analysis indicated heterogeneity in Subgroup 2 [RR ¼ 1.00
(95% CI: 0.98e103), statistic Z ¼ 0.25, p ¼ 0.80], and the
difference between the two groups was not statistically sig-
nificant. The combined subgroups used the random effects
model, with statistics after the merger utilizing hypothesis
testing, and the difference being not statistically significant
( p ¼ 0.23). The current evidence did not indicate that the
effective rate between the two groups was statistically sig-
nificant (Fig. 3).3.5. Safety evaluationThere were 18 studies that described the adverse drug
reactions.8e12,14,15,19e21,23,26e28,30e32,34 Of those studies,
Fig. 2. Meta-analysis of viral shedding: TCM versus control group. CI ¼ confidence interval; IV ¼ Inverse Variance methods; SD ¼ standard deviation;
TCM ¼ traditional Chinese medicine.
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studies recorded 97 cases of adverse reactions (34 cases in the
TCM group and 63 cases in the control group). The proportion
of adverse reactions in the two groups was determined by
Chi-square test, and the difference was statistically significant
(c2 ¼ 17.281, p < 0.001). Nine of these
studies8,9,11,12,19,23,31,32,34 reported nausea/vomiting in 29
cases: the TCM group included two cases and 27 cases in the
control group. Nine studies8,12,23,26,27,30e32,34 reported diar-
rhea in 23 patients: 11 cases in the TCM group and 12 cases in
the control group. There were five studies8,11,12,23,34 that re-
ported six cases of rash, all which occurred in the control
group. One study reported that the TCM group had one case of
watery stool and one case of arrhythmia; in that study, there
was one case of chest pain in the control group.14 One study
reported that the participants in the TCM group experienced
excessive sweating and diarrhea, whereas five patients in the
control group had lower white blood cell count.26 Another
study reported that the TCM group had three patients who had
secondary infection, and there was one control case of
abdominal pain.9 Two studies reported that neurological
symptoms appeared in six cases (all in the control group).30,31
In addition, one study reported only the number of adverse
reactions, noting that the TCM group had 11 cases and the
control group had seven, but did not state the specific nature of
the adverse reactions.364. Discussion
In this review, several Chinese herbal medicines demon-
strated a potentially positive effect on the influenza A (H1N1)
strain, especially on its time to defervescence, as in the studies
analyzed, the mean time to defervescence in the TCM treat-
ment group was less than that noted in the control group.
Furthermore, the duration of influenza A (H1N1) shedding in
the integrated Chinese and Western medicine subgroup was
less than that noted in the control group, although existing
evidence indicated that the difference in duration of viral
shedding and effective rate between the two groups was sta-
tistically similar. The applicability of the included studies was
limited, however, because their inclusion criteria, in-
terventions, durations, and outcome measures were different.
Consequently, more well-designed trials are required.4.1. Quality of the evidenceWe rated the quality of the evidence from the included
studies as very low to low, and the reasons for this are as
follows:
First, most of the retrieved studies did not provide adequate
descriptions about the methodology used, which may have
misled us (e.g., inclusion of nonrandomized trials and incor-
rect classification of the trials) if we had not clarified the
Fig. 3. Meta-analysis of effective rate: TCM versus control group. CI ¼ confidence interval; M-H ¼ Mantel-Haenszel methods; SD ¼ standard deviation;
TCM ¼ traditional Chinese medicine.
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necessary process to interview every primary author of the
trial before deciding whether to include the trials, when the
methodological details were not reported. Contacting authors
by telephone was more effective than corresponding by
writing because of a higher response rate. However, even after
confirmation of true randomization, we found that the meth-
odological quality of the studies remained poor.
Allocation concealment is an important marker of trial
quality. However, in our review, some articles failed to reportor perform allocation concealment, and this leads to a high
risk of selection and confounding bias.
Second, only 10 RCTs stated the randomization procedure
used.8,10e12,14,23,25,27,28,31 However, most of them provided
insufficient information to judge whether the randomization
process was conducted properly. For the balance of the trials,
it was just mentioned that “the patients were randomized into
two groups” and no further information was provided.
Therefore, we could not exclude the possibility that some of
these claimed RCTs were not real RCTs. This possibility came
289J.-H. Li et al. / Journal of the Chinese Medical Association 79 (2016) 281e291to the forefront in the trials conducted by Han 2011,18 Zhang
2011,25 and Li 2010.36 These trials only have one credited
author, and therefore, it would be impossible for an RCT to be
done properly in terms of randomization procedure and allo-
cation concealment. Only two trials claimed double blind.10,28
We understood that it was difficult to perform double blinding
because of certain features associated with Chinese herbs,
such as aroma and appearance; however, blinding to the
outcome assessors and data analyzer could be feasible. All the
trials except two did not report presample size estimation,10,28
and for a majority of the trials, the sample size was small.
Therefore, we are not sure if they could provide sufficient
statistical power to detect the difference between groups. It is
well-known that poorly designed trials show larger differences
between the experimental and control groups than those con-
ducted rigorously,39,40 and as such the small improvements in
outcomes should be regarded with caution.
Third, there was lack of knowledge on placebo control in
the included trials. Only one Chinese herbal injection was used
in the review (Tanreqing injection),17,19,30 and all demon-
strated positive results in terms of defervescence and global
symptoms improvement. However, no adequate placebo con-
trol was used to offset the effect of the injection alone. It is
known that an injection alone has a strong potential placebo
effect, and therefore, the overall effect of a Chinese herbal
injection could not rule out the effect that the injection itself
produced. These positive effects should also be interpreted
conservatively.
Finally, among high-quality studies, we found that the data
reported for time to defervescence were inconsistent. How-
ever, data on duration of viral shedding and effective rate in
these studies were consistent, suggesting that study qualityTable 2
Adverse reactions record.
Study Sample Adverse
reactions
E C E
Zhang et al27 2012 84 84 Yes No
Chen et al14 2010 48 47 Yes 1 case of watery and 1 case
of arrhythmia
Liu et al15 2010 64 60 Yes No
Tang et al20 2013 57 63 Yes No
Zeng et al11 2011 59 55 Yes No
Zhao et al26 2011 31 16 Yes 1 case of sweat and diarrhea
Zheng et al21 2010 52 51 Yes No
Chen et al12 2011 31 55 Yes 1 case of diarrhea,
Chen et al8 2010 31 22 Yes 1 case of diarrhea
Ma et al19 2010 133 147 Yes No
Liu et al23 2011 31 21 Yes 1 case of diarrhea
Wang et al28 2011 103 103 Yes No
OuYang et al9 2010 116 58 Yes 3 cases of secondary infection
Wei and Luo30 2010 30 16 Yes 2 cases of diarrhea
Zhang et al31 2010 56 56 Yes 4 cases of diarrhea
Weng et al32 2010 150 150 Yes No
Tu et al34 2013 128 107 Yes 2 cases of nausea and vomiting
1 case of diarrhea
Duan et al10 2011 122 122 Yes 11 cases
C ¼ control group; E ¼ experimental group.may affect the results of the analysis. Thus, there is a need to
increase the quality of such studies for further evaluation.4.2. Select interventionsIn TCM practice, herbal preparations should match the type
of syndrome differentiation, that is, bianzheng, a specific
diagnosis in TCM. This approach is also known as “treatment
based on individualized (tailored) syndrome pattern,” and is
thought to be one of the advantages of TCM. However, in this
review, only eight trials provided information on patients'
syndrome differentiation.8,12,19,20,23,26,27,37 Chinese medicine
practitioners believed that treating patients without syndrome
differentiation will impair the advantages of Chinese herbs,
and this might be another reason for the unsatisfactory ther-
apeutic effect of Chinese herbs on H1N1 influenza in the re-
view. Thus, there is a need to encourage authors to explain
each “Bianzheng” using common medical terms in future
trials, which would make their study more understandable for
physicians and consumers.
The control group interventions (oseltamivir as a main
therapeutic drug) were more reasonable, except for two
studies. Oseltamivir (Tamiflu) is approved by the US FDA for
use against Type A and Type B influenza infections.4.3. Adverse drug reactionsWithin our study, 18 studies reported adverse drug reac-
tions.8e12,14,15,23,26e28,30,31,34 The adverse reactions were
shown in Table 2. Those studies recorded 97 cases of adverse
reactions (34 in the treatment group and 63 in the control
group). Given the proportion of adverse reactions in theAdverse reactions record
C
5 cases of diarrhea
1 case of pneumonia and 1 case of chest pain
No
No
2 cases of nausea and vomiting, 1 case of rash
5 cases had lower white blood cell count
No
1 case of rash, 2 cases of vomiting
1 case of rash, 3 cases of nausea and vomiting
4 cases of nausea, loss of appetite
2 cases of rash, 2 cases of vomiting
1 case of nausea and vomiting
1 case of abdominal pain
2 cases of diarrhea, 1 case of nausea, 1 case of neurological symptoms
6 cases of nausea, vomiting, 5 cases of neurological symptoms
6 cases of nausea, 3 cases of diarrhea
, 2 cases of nausea and vomiting, 1 case of abdominal pain, 1 case of rash
7 cases
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view found inadequate reporting on adverse events in the
included trials. In fact, 11 trials did not mention whether they
had monitored adverse effects at all. Ultimately, conclusions
about the safety of herbal medicines cannot be drawn from this
review due to the limited, inadequate recording and reporting
of adverse events. Even for those trials that reported adverse
events, the reports were very brief and provided limited in-
formation. In China, there is a general perception that it is safe
to use herbal medicines for various conditions. However, with
the increasing reports of liver toxicity and other adverse events
associated with Chinese herbal medicines,41,42 there should be
more emphasis on the monitoring and reporting of adverse
events to justify the safety of Chinese herbs in clinical trials in
the future.4.4. Agreements and disagreements with other studies or
reviewsThe results of well-designed RCTs with large sample sizes
in the future may confirm or refute our conclusions. There is
one known systematic review of TCM for influenza,43 where
the results indicated that most Chinese medical herbs in the
included studies showed effects similar to antiviral drugs in
preventing or treating influenza. Few were shown to be su-
perior to antiviral drugs, and no obvious adverse events were
reported in the included studies. In summary, previous studies
showed that administration of some Chinese herbs may have
beneficial immunomodulatory effects for rapid recovery from
viral infections.42,44 However, in this review, it would appear
that compared with oseltamivir, Chinese herbs might have
superior potential effects on fever resolution than viral
shedding, which also suggests that most Chinese herbs may
not have antiviral effects. In the era of evidence-based
medicine, TCM is facing a substantial challenge because of
the lack of rigorous evidence-based research. Our review
attempted to bring a measure of elucidation into the clinical
use and policy making of Chinese herbs for H1N1 influenza
in China. However, considerable work needs to be done
before the evidence-based practice of TCM can become a
reality.
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